title: Chemotherapy alone for organ preservation in advanced laryngeal cancer.
abstract: BACKGROUND
  For patients with advanced laryngeal cancer, a trial was designed to determine if chemotherapy alone, in patients achieving a complete histologic complete response after a single neoadjuvant cycle, was an effective treatment with less morbidity than concurrent chemoradiotherapy.
  
  
  METHODS
  Thirty-two patients with advanced laryngeal or hypopharyngeal cancer received 1 cycle of induction chemotherapy, and subsequent treatment was decided based on response.
  
  
  RESULTS
  A histologic complete response was achieved in 4 patients and were treated with chemotherapy alone. All 4 patients' cancer relapsed in the neck and required surgery and postoperative radiotherapy (RT). Twenty-five patients were treated with concomitant chemoradiation. Three patients were treated with surgery. Overall survival and disease-specific survival at 3 years were 68% and 78%, respectively.
  
  
  CONCLUSIONS
  Chemotherapy alone is not feasible for long-term control of regional disease in patients with advanced laryngeal cancer even when they achieve a histologic complete response at the primary site.
authors: Department of Otolaryngology-Head and Neck Surgery, Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI, USA.
authors: Vasu
authors: V
authors: Divi
authors: Francis P
authors: FP
authors: Worden
authors: Mark E
authors: ME
authors: Prince
authors: Avraham
authors: A
authors: Eisbruch
authors: Julia S
authors: JS
authors: Lee
authors: Carol R
authors: CR
authors: Bradford
authors: Douglas B
authors: DB
authors: Chepeha
authors: Theodoros N
authors: TN
authors: Teknos
authors: Norman D
authors: ND
authors: Hogikyan
authors: Jeffrey S
authors: JS
authors: Moyer
authors: Christina I
authors: CI
authors: Tsien
authors: Susan G
authors: SG
authors: Urba
authors: Gregory T
authors: GT
authors: Wolf
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D016190:Carboplatin / Q000627:therapeutic use; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D002945:Cisplatin / Q000627:therapeutic use; D003131:Combined Modality Therapy; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D007012:Hypopharyngeal Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D007822:Laryngeal Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D016190:Carboplatin; D002945:Cisplatin; D005472:Fluorouracil